A novel ex vivo high-throughput assay reveals antiproliferative effects of idelalisib and ibrutinib in chronic lymphocytic leukemia

PI3Kδ (idelalisib) and BTK (ibrutinib) inhibitors have demonstrated significant clinical activity in chronic lymphocytic leukemia (CLL) interfering with the cross-talk between CLL cells and the lymph node microenviroment, yet their mechanism of action remains to be fully elucidated. Here, we develop...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncotarget
Asıl Yazarlar: Primo, Daniel, Scarfò, Lydia, Xochelli, Aliki, Mattsson, Mattias, Ranghetti, Pamela, Espinosa, Ana Belén, Robles, Alicia, Gorrochategui, Julian, Martínez-López, Joaquín, de la Serna, Javier, González, Marcos, Gil, Alberto Chaparro, Anguita, Eduardo, Iraheta, Sandra, Munugalavadla, Veerendra, Quéva, Christophe, Tannheimer, Stacey, Rosenquist, Richard, Stamatopoulos, Kostas, Ballesteros, Joan, Ghia, Paolo
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Impact Journals LLC 2018
Konular:
Research Paper
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5995261/
https://ncbi.nlm.nih.gov/pubmed/29899839
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25419
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller